| Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg, S Potdar, A Kyttälä, ... BMC cancer 19, 1-14, 2019 | 64 | 2019 |
| The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy E Skaga, IØ Skaga, Z Grieg, CJ Sandberg, IA Langmoen, EO Vik-Mo Journal of cancer research and clinical oncology 145, 1495-1507, 2019 | 49 | 2019 |
| Phenotypic and expressional heterogeneity in the invasive glioma cells A Fayzullin, CJ Sandberg, M Spreadbury, BM Saberniak, Z Grieg, ... Translational oncology 12 (1), 122-133, 2019 | 38 | 2019 |
| Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply? E Skaga, MA Skretteberg, TB Johannesen, P Brandal, EO Vik-Mo, ... Neuro-Oncology Advances 3 (1), vdab008, 2021 | 37 | 2021 |
| Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment E Skaga, E Kulesskiy, M Brynjulvsen, CJ Sandberg, S Potdar, ... Clinical and translational medicine 8, 1-15, 2019 | 24 | 2019 |
| A small-molecule tankyrase inhibitor reduces glioma stem cell proliferation and sphere formation KS Kierulf-Vieira, CJ Sandberg, J Waaler, K Lund, E Skaga, ... Cancers 12 (6), 1630, 2020 | 20 | 2020 |
| HMGB1 concentration measurements in trauma patients: assessment of pre-analytical conditions and sample material W Ottestad, IN Rognes, E Skaga, C Frisvoll, G Haraldsen, T Eken, ... Molecular Medicine 26, 1-8, 2020 | 10 | 2020 |
| Nuclear magnetic resonance spectroscopy to identify metabolite biomarkers of nonresponsiveness to targeted therapy in glioblastoma tumor stem cells IC Hvinden, HE Berg, D Sachse, E Skaga, FS Skottvoll, E Lundanes, ... Journal of proteome research 18 (5), 2012-2020, 2019 | 7 | 2019 |
| Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome E Skaga, E Kulesskiy, S Potdar, I Panagopoulos, F Micci, IA Langmoen, ... Translational oncology 26, 101535, 2022 | 2 | 2022 |
| Drug sensitivity and resistance testing of brain tumor stem cells for individualized functional precision medicine E Skaga | 2 | 2021 |
| The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study EE Mendoza Mireles, E Skaga, A Server, H Leske, P Brandal, E Helseth, ... Neuro-Oncology Practice 10 (6), 555-564, 2023 | 1 | 2023 |
| Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study. E Skaga, CB Trewin-Nybråten, P Niehusmann, TB Johannesen, ... Acta Oncologica (Stockholm, Sweden) 63, 83-94, 2024 | | 2024 |
| Functional and Molecular Heterogeneity in Glioma Stem Cells Derived from Multiregional Sampling M Brynjulvsen, E Solli, M Walewska, M Zucknick, L Djirackor, ... Cancers 15 (24), 5826, 2023 | | 2023 |
| PREOPERATIVE NANO SCORE AS A PREDICTOR FOR SURVIVAL IN GLIOBLASTOMA EM Mireles, HK Blakstad, E Skaga, E Helseth, P Ronning, E Vik-Mo NEURO-ONCOLOGY 25, 2023 | | 2023 |
| THE EFFECT OF COMPLETE RESECTION OF CONTRAST-ENHANCING TUMOR ON SURVIVAL IN PATIENTS WITH GLIOBLASTOMA OVER A 16-YEAR PERIOD IN A GEOGRAPHICALLY DEFINED POPULATION EEM Mireles, EO Vik-Mo, E Skaga, E Helseth, PA Ronning, A Server, ... NEURO-ONCOLOGY 24, 234-234, 2022 | | 2022 |
| TBIO-18. ESTABLISHING A PIPELINE FOR INDIVIDUALIZED TREATMENT OPTIONS FOR PEDIATRIC BRAIN CANCER L Djirackor, S Halldorsson, C Sandberg, P Euskirchen, E Skaga, ... Neuro-oncology 22 (Suppl 3), iii470, 2020 | | 2020 |
| EPID-25. HOW MANY PATIENTS IN A REAL WORLD GLIOBLASTOMA POPULATION MEET ELIGIBILITY CRITERIA IN CLINICAL TRIALS? E Skaga, MA Skretteberg, TB Johannesen, P Brandal, EO Vik-Mo, ... Neuro-oncology 21 (Suppl 6), vi80, 2019 | | 2019 |
| ACTR-79. ESTABLISHMENT OF CLINICAL PROTOCOL TARGETING CANCER STEM CELLS IN RECURRENT GLIOBLASTOMA USING HIGH-THROUGHPUT DRUG SCREENING E Skaga, E Kulesskiy, M Brynjulfsen, CJ Sandberg, A Kyttälä, ... Neuro-oncology 19 (suppl_6), vi18-vi18, 2017 | | 2017 |
| DDIS-13. IDENTIFICATION OF INDIVIDUALIZED THERAPY OPTIONS IN PATIENTS WITH GLIOBLASTOMA BY HIGH-THROUGHPUT DRUG SCREENING E Skaga, E Kulesskiy, CJ Sandberg, A Fayzullin, A Kyttälä, IA Langmoen, ... Neuro-Oncology 18 (suppl_6), vi50-vi50, 2016 | | 2016 |
| Kan det innføres måling av skademarkøren S100B i utredningen av lette hodeskader hos voksne ved Oslo skadelegevakt? E Skaga, L Veiteberg, CG Eikeseth, GR Jenssen, M Mousavi, AO Norgren | | 2014 |
Cecilie SandbergVilhelm Magnus Center for Neurosurgical ResearchVerified email at rr-research.no
